Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Open access
Smith, Rona M, Jones, Rachel Bronwen, Specks, Ulrich, Bond, Simon, Nodale, Marianna, Aljayyousi, Reem, Andrews, Jacqueline, Bruchfeld, Annette, Camilleri, Brian, Carette, Simon, Cheung, Chee Kay, Derebail, Vimal, Doulton, Tim, Forbess, Lindsy, Fujimoto, Shouichi, Furuta, Shunsuke, Gewurz-Singer, Ora, Harper, Lorraine, Ito-Ihara, Toshiko, Khalidi, Nader, Klocke, Rainer, Koening, Curry, Komagata, Yoshinori, Langford, Carol, Lanyon, Peter, Luqmani, Raashid Ahmed, Makino, Hirofumi, McAlear, Carole, Monach, Paul, Moreland, Larry W, Mynard, Kim, Nachman, Patrick, Pagnoux, Christian, Pearce, Fiona, Peh, Chen Au, Pusey, Charles, Ranganathan, Dwarakanathan, Rhee, Rennie L, Spiera, Robert, Sreih, Antoine G, Tesar, Vladimir, Walters, Giles, Weisman, Michael H, Wroe, Caroline, Merkel, Peter, Jayne, David · 2020 · Annals of the Rheumatic Diseases

Abstract

OBJECTIVES: Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial. METHODS: ) and a higher or lower dose glucocorticoid regimen, depending on physician choice: reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Patients in this cohort achieving remission were subsequently randomised to receive one of two regimens to prevent relapse. RESULTS: 188 patients were studied: 95/188 (51%) men, median age 59 years (range 19-89), prior disease duration 5.0 years (range 0.4-34.5). 149/188 (79%) had previously received cyclophosphamide and 67/188 (36%) rituximab. 119/188 (63%) of relapses had at least one major disease activity item, and 54/188 (29%) received the higher dose glucocorticoid regimen. 171/188 (90%) patients achieved remission by 4 months. Only six patients (3.2% of the study population) did not achieve disease control at month 4. Four patients died in the induction phase due to pneumonia (2), cerebrovascular accident (1), and active vasculitis (1). 41 severe adverse events occurred in 27 patients, including 13 severe infections. CONCLUSIONS: This large prospective cohort of patients with relapsing AAV treated with rituximab in conjunction with glucocorticoids demonstrated a high level of efficacy for the reinduction of remission in patients with AAV who have relapsed, with a similar safety profile to previous studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2019-216863

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 174

Metadata

Authors
Smith, R. M., Jones, R. B., Specks, U., Bond, S., Nodale, M., Aljayyousi, R., Andrews, J., Bruchfeld, A., Camilleri, B., Carette, S., Cheung, C. K., Derebail, V., Doulton, T., Forbess, L., Fujimoto, S., Furuta, S., Gewurz-Singer, O., Harper, L., Ito-Ihara, T., Khalidi, N., Klocke, R., Koening, C., Komagata, Y., Langford, C., Lanyon, P., Luqmani, R. A., Makino, H., McAlear, C., Monach, P., Moreland, L. W., Mynard, K., Nachman, P., Pagnoux, C., Pearce, F., Peh, C. A., Pusey, C., Ranganathan, D., Rhee, R. L., Spiera, R., Sreih, A. G., Tesar, V., Walters, G., Weisman, M. H., Wroe, C., Merkel, P., & Jayne, D.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2020-09
Volume
79
Issue
9
Pages
1243-1249
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3037338668
Cited by
174
References
1
FWCI
13.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. https://app.cochat.ai/papers/10.1136/annrheumdis-2019-216863
The paper
Smith, R. M., Jones, R. B., Specks, U., Bond, S., Nodale, M., Aljayyousi, R., Andrews, J., Bruchfeld, A., Camilleri, B., Carette, S., Cheung, C. K., Derebail, V., Doulton, T., Forbess, L., Fujimoto, S., Furuta, S., Gewurz-Singer, O., Harper, L., Ito-Ihara, T., . . . Jayne, D. (2020). Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2019-216863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.